Thermo Fisher to acquire Olink for $26/share, ~$3.1B total

THERMO FISHER SCIENTIFIC INC.

Cash tender offer at $26/ADS, ~74% premium to Oct 16 close; transaction values Olink at ~$3.1B including ~$143M net cash.
Expected close mid-2024; support agreements from >63% of Olink shareholders including largest shareholder Summa Equity.
Olink projected >$200M revenue in 2024 with mid-teens organic growth; expected to be part of Thermo Fisher's Life Sciences Solutions segment.
Transaction expected to be $0.17 dilutive to adjusted EPS in first full year, but $0.10 accretive excluding financing and equity comp.
Thermo Fisher expects ~$125M adjusted operating income from synergies by year five.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.